跳至主要内容
临床试验/EUCTR2021-001069-20-ES
EUCTR2021-001069-20-ES进行中(未招募)1 期

Tolerability and acceptance of two oral hydrocortisone compounding formulation for pediatrics

Vall d'Hebron Hospital Universitari0 个研究点目标入组 35 人开始时间: 2021年8月12日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
35

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Outpatients of both sexes, = 6 years of age without swallowing problems and up to 17 years, at the time of signing the informed consent document by parent (s) or guardian (s) and / or patients.
  • - Diagnosis of adrenal hyperplasia or isolated primary adrenal insufficiency or panhypopituitarism (secondary or tertiary adrenal insufficiency)
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 35
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Known hypersensitivity to any of the excipients in the hydrocortisone compounding.
  • -Any disorder or situation (decompensation) that, in the opinion of the medical researcher, poses a risk of not complying with the treatment.

研究者

发起方
Vall d'Hebron Hospital Universitari

相似试验